[go: up one dir, main page]

SG10201700596PA - Stabilized pharmaceutical dosage forms comprising atrasentan - Google Patents

Stabilized pharmaceutical dosage forms comprising atrasentan

Info

Publication number
SG10201700596PA
SG10201700596PA SG10201700596PA SG10201700596PA SG10201700596PA SG 10201700596P A SG10201700596P A SG 10201700596PA SG 10201700596P A SG10201700596P A SG 10201700596PA SG 10201700596P A SG10201700596P A SG 10201700596PA SG 10201700596P A SG10201700596P A SG 10201700596PA
Authority
SG
Singapore
Prior art keywords
atrasentan
dosage forms
pharmaceutical dosage
stabilized pharmaceutical
stabilized
Prior art date
Application number
SG10201700596PA
Inventor
Ye Huang
Andrew K Koski
Katherine E Peterson
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG10201700596PA publication Critical patent/SG10201700596PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201700596PA 2013-07-08 2014-07-07 Stabilized pharmaceutical dosage forms comprising atrasentan SG10201700596PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361843799P 2013-07-08 2013-07-08

Publications (1)

Publication Number Publication Date
SG10201700596PA true SG10201700596PA (en) 2017-02-27

Family

ID=51211921

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201600107RA SG11201600107RA (en) 2013-07-08 2014-07-07 Stabilized pharmaceutical dosage forms comprising atrasentan
SG10201700596PA SG10201700596PA (en) 2013-07-08 2014-07-07 Stabilized pharmaceutical dosage forms comprising atrasentan

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201600107RA SG11201600107RA (en) 2013-07-08 2014-07-07 Stabilized pharmaceutical dosage forms comprising atrasentan

Country Status (19)

Country Link
US (2) US9364458B2 (en)
EP (1) EP3019158A1 (en)
JP (1) JP2016530238A (en)
KR (1) KR20160029125A (en)
CN (1) CN105517541A (en)
AU (1) AU2014287496A1 (en)
CA (1) CA2916033C (en)
CL (2) CL2016000027A1 (en)
CR (1) CR20160037A (en)
DO (1) DOP2016000003A (en)
EC (1) ECSP16005195A (en)
HK (1) HK1223825A1 (en)
IL (1) IL243242B (en)
MX (1) MX2016000188A (en)
PE (1) PE20160221A1 (en)
PH (1) PH12016500042A1 (en)
RU (1) RU2016103764A (en)
SG (2) SG11201600107RA (en)
WO (1) WO2015006219A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600107RA (en) * 2013-07-08 2016-02-26 Abbvie Inc Stabilized pharmaceutical dosage forms comprising atrasentan
US10929741B2 (en) 2018-06-18 2021-02-23 University Of Florida Research Foundation, Incorporated Cross-registration for unclonable chipless RFID tags
IL293921A (en) 2019-12-17 2022-08-01 Chinook Therapeutics Inc Methods for treating iga kidney disease with atresantan
WO2022009163A1 (en) 2020-07-10 2022-01-13 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease
US12156914B2 (en) * 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
IL320469A (en) 2022-10-28 2025-06-01 Chinook Therapeutics Inc Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (en) 1990-01-23 1999-01-15 . Cyclodextrin derivatives with increased water solubility and uses thereof
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US6124341A (en) 1996-02-13 2000-09-26 Abbott Laboratories Endothelin antagonists
US5801250A (en) 1996-12-13 1998-09-01 Abbott Laboratories Process for the stereoselective production of nitro-enamine compounds
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2002524546A (en) 1998-09-14 2002-08-06 アボット・ラボラトリーズ Method for producing stereoselective nitro compound
US20020055457A1 (en) 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030022811A1 (en) 2001-04-11 2003-01-30 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US20030092757A1 (en) 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20060135596A1 (en) * 2004-09-17 2006-06-22 Zhang Geoff G Amorphous form of a drug
US9051301B2 (en) 2004-09-17 2015-06-09 Abbvie Inc. Crystalline form of a drug
WO2006034094A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride
EP1802610A1 (en) * 2004-09-17 2007-07-04 Abbott Laboratories Crystalline form 2 of atrasentan hydrochloride
EP2001446A2 (en) * 2006-03-13 2008-12-17 Encysive Pharmaceuticals, Inc Formulations of sitaxsentan sodium
US20080132710A1 (en) 2006-12-04 2008-06-05 Abbott Laboratories Atrasentan hydrochloride crystalline form 2
US20100184026A1 (en) 2009-01-22 2010-07-22 Abbott Laboratories Companion Diagnostic Assays For Endothelin Receptor Antagonists
WO2011079127A1 (en) * 2009-12-22 2011-06-30 Abbott Laboratories Abt-263 capsule
KR20110119108A (en) 2010-04-26 2011-11-02 울산대학교 산학협력단 Pharmaceutical composition for treating and preventing pulmonary fibrosis containing grape seed proanthocyanidin extract as an active ingredient
CN102114005B (en) * 2010-12-06 2012-12-12 武汉武药科技有限公司 Tracleer capsule and preparation method thereof
SG11201600107RA (en) * 2013-07-08 2016-02-26 Abbvie Inc Stabilized pharmaceutical dosage forms comprising atrasentan
US8962675B1 (en) * 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts

Also Published As

Publication number Publication date
HK1223825A1 (en) 2017-08-11
CN105517541A (en) 2016-04-20
CR20160037A (en) 2016-04-05
JP2016530238A (en) 2016-09-29
WO2015006219A1 (en) 2015-01-15
CL2016000788A1 (en) 2016-11-11
CA2916033A1 (en) 2015-01-15
PH12016500042A1 (en) 2016-03-28
US20160250186A1 (en) 2016-09-01
US10016393B2 (en) 2018-07-10
PE20160221A1 (en) 2016-05-22
IL243242A0 (en) 2016-02-29
RU2016103764A (en) 2017-08-11
RU2016103764A3 (en) 2018-05-31
ECSP16005195A (en) 2017-02-24
KR20160029125A (en) 2016-03-14
SG11201600107RA (en) 2016-02-26
MX2016000188A (en) 2016-03-09
CA2916033C (en) 2022-08-23
US9364458B2 (en) 2016-06-14
IL243242B (en) 2020-11-30
US20150011602A1 (en) 2015-01-08
DOP2016000003A (en) 2016-02-15
CL2016000027A1 (en) 2016-07-22
EP3019158A1 (en) 2016-05-18
AU2014287496A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
GB201322602D0 (en) Pharmaceutical compounds
GB201306610D0 (en) Pharmaceutical compounds
ZA201403276B (en) Low dose pharmaceutical composition
ZA201602047B (en) Pharmaceutical compounds
ZA201507576B (en) Pharmaceutical combination drug
IL243242A0 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
IL245705A0 (en) Pharmaceutical dosage forms
SG11201509194SA (en) Radiomitigating pharmaceutical formulations
ZA201600027B (en) Pharmaceutical preparation
GB201312386D0 (en) Pharmaceutical compounds
GB201413253D0 (en) Solid dosage form
GB201317166D0 (en) Pharmaceutical compounds
ZA201506465B (en) Pharmaceutical preparation
GB201316780D0 (en) Pharmaceutical compounds
GB201316791D0 (en) Pharmaceutical Compounds
GB201315734D0 (en) Pharmaceutical compounds
GB201315733D0 (en) Pharmaceutical compounds
GB201312464D0 (en) Pharmaceutical compounds
GB201308781D0 (en) Pharmaceutical compounds
GB201308780D0 (en) Pharmaceutical compounds
GB201308782D0 (en) Pharmaceutical compounds
GB201316662D0 (en) Pharmaceutical Combination
GB201309405D0 (en) Pharmaceutical compound